The review found no eligible studies for this question.
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
It is very uncertain whether withdrawal of anticholinergic medication changes acceptability of the treatment: leaving the study early compared with continuing anticholinergic medication (very low certainty).
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with non‐Intensive Case Management (low certainty).
Intensive Case Management may leads to lower global state: 1. Leaving the study early ‐ by long term compared with standard care (low certainty).
VIDEO GAMES (EXERGAMES) (plus standard care) showed no clear difference in adverse effects*: leaving the study early ‐ did not leave compared with STANDARD CARE (low certainty).
The review found no eligible studies for this question.
Group cognitive behavioural therapy for psychosis showed no clear difference in leaving the study early: for any reason – end of treatment compared with standard care (low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with perphenazine (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with risperidone (very low certainty).